DalCor Pharmaceuticals US, LLC — SEC Form D Filing
DalCor Pharmaceuticals US, LLC filed an SEC Form D on August 28, 2026, reporting $6.96M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- August 28, 2026
- Amount reported
- $6.96M
- Round stage
- Series A because a $6.9 million equity raise is typical for an early-stage clinical biotechnology company transitioning into larger clinical trials.
- Industry
- Pharmaceuticals
- Website
- https://www.dalcorpharma.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Coronary artery disease and cardiovascular conditions require targeted, genetically-guided therapeutic interventions to reduce adverse clinical outcomes in specific patient populations.
Solution
DalCor Pharmaceuticals US conducts clinical trials and develops targeted pharmaceutical therapies aimed at treating coronary artery disease and preventing cardiovascular events.
Why now
Advancements in precision medicine and pharmacogenomics now enable researchers to target cardiovascular therapies to specific genetic profiles for higher efficacy.
Source: SEC EDGAR Form D filing